The Coronavirus Is Mutating. What Does That Mean for a

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
191
The Coronavirus Is Mutating. What Does That Mean for a Vaccine?
< >



Around the world, hope for a return to normalcy is pinned on a vaccine, the “ultimate weapon,” as it’s been called by officials like Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. But it’s still unclear how successful a vaccine against SARS-CoV-2, the virus that causes Covid-19, can be.

A lot will depend on how the virus mutates. Broadly, there are two ways mutations can play out.
Scenario 1: The coronavirus is unable to evade a vaccine

A successful vaccine could stop the virus dead in its tracks, but only if the virus doesn't mutate its way around the shot. Here's what scientists are watching for:

Like all viruses, SARS-CoV-2 is mutating as it passes from person to person. A “mutation” is just a change in a virus’s genetic code. Most mutations don’t really change how the virus functions.

Below is a glimpse at an imaginary virus. It’s doing what all viruses do: entering a cell, hijacking the cell’s machinery and using it to make many copies of itself.

Sometimes, small errors — or mutations — can show up in that replication. Those errors accumulate over time as the virus spreads from cell to cell and person to person.

Vaccines work by prompting the body to develop antibodies, which neutralize the virus by binding to it in a very specific way. Scientists are watching to see if mutations will affect this interaction. If they don't, then there is hope that a vaccine won't need constant updating

That same process has played out with our most effective vaccines, including the one against measles.

“Measles mutates just as fast as flu and coronavirus, but the measles vaccine from 1950 still works today,” said Trevor Bedford, a biologist at the Fred Hutchinson Cancer Research Center in Seattle.

To enter a cell, the measles virus uses certain of its proteins that are unable to mutate even slightly without breaking. The vaccine targets those parts, so any mutation that would evade the vaccine would mean that the virus can’t infect other cells.

The vaccine has the measles virus cornered.
Scenario 2: Mutations make vaccines less effective over time

But what if the virus doesn’t get cornered like measles? If the virus mutates in a way that prevents antibodies from binding, it could make a lasting, universal vaccine difficult to create.

Antibodies, which the body produces in response to a vaccine or an infection, work by binding to specific spots on a virus called antigens. If random viral mutations alter the shape of an antigen, it can make a vaccine less effective against the virus.

"What will happen in many viruses is you'll get infected by Strain A; your immune system learns to recognize that surface protein, but then the virus is able to mutate in such a fashion that it still performs its function but make it so that your antibodies against Strain A no longer recognize Strain B," Dr. Bedford said.

Here’s that scenario playing out on our fictional virus: The antibodies produced by the vaccine work on one strain but can’t bind to the other, rendering the vaccine ineffective.

That’s what happens with the flu: The virus’s antigens mutate so much that they evolve into different strains, each requiring a slightly different vaccine. Scientists continuously develop vaccines to target those new strains. In spite of that, the vaccines offer only partial immunity to the various flu strains that spread each year.

If that happens with the coronavirus, researchers will have to rush to produce and administer new vaccines as novel strains of the virus naturally arise.

It also reveals another quirk with how viruses behave: Some can respond to the immunity in the population they’re trying to infect. Over time, for example, many people develop immunity to at least some strains of the flu — either through fighting off infections or by getting vaccinated. But the virus keeps spreading. Here’s how.

For a brand-new virus like SARS-CoV-2, there is no widespread immunity. This virus is encountering few immune hosts who could halt its spread. Since the virus doesn’t need to change to survive, mutations that could modify the shape of the antigens — if they exist at all — are likely rare, and will stay rare.

But if people become immune to the dominant strain, either by fighting off the virus or through vaccination, the game changes. Versions of the virus with mutations that get around the population’s immunity are more likely to spread, and can then develop into new strains.

The takeaway: We’ll have to wait and see

Scientists know that SARS-CoV-2 is mutating.

Among the thousands of samples of the long strand of RNA that makes up the coronavirus, 11 mutations have become fairly common. But as far as we know, it’s the same virus infecting people all over the world, meaning that only one “strain” of the virus exists, said Peter Thielen, a molecular biologist with the Johns Hopkins Applied Physics Laboratory.

Only one of those common mutations affects the “spike protein,” which enables the virus to infect cells in the throat and lungs. Efforts to produce antibodies that block the spike protein are central to many efforts to develop a vaccine. Since the spike protein has changed little so far, some scientists believe that’s a sign that it can’t alter itself very much and remain infectious.

There’s still a lot about the virus we don’t know. We don’t even know if people are immune to the virus if they’ve caught it already, nor how long that immunity could last, though work is well underway to understand these things.

Mr. Thielen says it is still unclear how those mutations in the genome will ultimately affect countermeasures like a vaccine.

“We just have to keep looking,” he said.

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Andavi Acquires Infilect: Shaping Future of Retail AI

Updated Category News Views 104

Big Moves in Retail AI: Andavi Snaps Up Infilect Here we go, folks! Andavi Solutions just dropped a doozy on the market. They've bagged Infilect, an AI technology headliner based in Bengaluru, and it's got some tongues wagging. The New York-headquartered outfit, known for its slick sales execution tech in the beverage and consumer goods sectors, is betting big on AI. And...

Continue Reading
Eunice Goldstein Winery's Luxe Holiday Gifting Revolution

Updated Category News Views 138

Shaking Up the Holiday Gifting Game You ever feel like holiday gifting is stuck in a rut? Same old generic bottles and baskets. But, here comes Eunice Chiweshe Goldstein Winery, charging in with a fresh take on holiday generosity. This ain't just about selling wine—this is about crafting an experience for both giver and receiver. Perfect for those looking to ditch the...

Continue Reading
Smartphone Durability: What Investors Need to Know

Updated Category News Views 109

When a Drop Becomes a Cost-Benefit Analysis As someone who’s been around the block more times than I care to count, here’s a nugget for you: we rarely think about all the little things that could drill a hole in our pockets until they do. Take smartphones, the ubiquitous little beasts we carry everywhere. An accidental drop, one moment you’re butterfingering it in...

Continue Reading
AVENIR GLOBAL Snaps Up Marker Collective: Bold Move

Updated Category News Views 12

AVENIR GLOBAL Expands Its Empire In what looks like a bold stride forward, AVENIR GLOBAL's acquisition of Marker Collective ain't just some casual Sunday stroll. This is a hefty leap into the big league of communications, catapulting the Montreal-based outfit into the ranks of the world's top 15 firms by revenue. Might say it's one hell of a way to celebrate the company's...

Continue Reading
Freedom Bank Taps McIntyre as CRE Powerhouse Leader

Updated Category News Views 77

Dan McIntyre's latest move to Freedom Bank of Virginia as Senior Vice President screams strategy. This isn’t just another shuffle of executive chairs—it’s a calculated play to deepen their roots in the fiercely competitive Washington D.C. real estate market. Now, why should investors like you sit up and take notice? Well, when a bank with hefty capital and a yawning...

Continue Reading
AAN Seeks Donations to Drive Crucial Brain Research

Updated Category News Views 58

Boosting Brain Horizons: The Need for Donations Urgency clings to the air like smoke around a campfire when it comes to funding brain research. The American Academy of Neurology (AAN) knows this, and they've kicked off their year-end giving campaign, trying to rope in every penny they can muster for the AAN Research Program. With brain diseases lining up like unwanted...

Continue Reading
Nutramax Boosts Young Scientists with Lindau Sponsorship

Updated Category News Views 68

Nurturing the Next Generation with Nobel Insights If you think science is just numbers and facts, you'd better wrap your head around what Nutramax Laboratories is pulling off. The company sent five bright-eyed young scientists to the 75th Lindau Nobel Laureate Meeting in Germany, where minds sharper than a new scalpel gather to shape the frontiers of research. This isn't...

Continue Reading
Pavlus Travel's Bucket-List Trips in High Demand for 2027

Updated Category News Views 16

Luxury Travel is Having a Moment A fancy vacation isn't just a postcard on the wall anymore—it's now, more than ever, a box folks are itching to check off their lists. Call it a midlife shift or just the world shrugging off its pandemic blues, but high-end travelers are saying, "The time is now," and they're serious. Pavlus Travel, a top name in the lux travel space,...

Continue Reading
Fingercheck Teams with Meridio to Secure Employee Health

Updated Category News Views 148

New Opportunities for Small Business Employees Man, oh man, the little guy finally gets a seat at the table, thanks to Fingercheck. This latest scoop? They've partnered with Meridio, so now small and mid-sized businesses can offer medical, dental, and vision coverage just like the big shots. It's about time, right? These folks have been left out in the cold far too long...

Continue Reading
AMTD IDEA Eyes Third NYC Hotel Amid Uncertain Deals

Updated Category News Views 50

AMTD IDEA's Expansive NYC Hotel Pursuits When it comes to real estate, AMTD IDEA seems to be on a buying spree in the Big Apple. The company is now eyeballing a third hotel in New York City, marking what could be yet another bold move in its strategic expansion. But let's be frank: deals like these come with their fair share of volatility. As it stands, they're in...

Continue Reading

Top 5 Most Recently Viewed Articles

NeurAxis Sees Revenue Surge and Expanded FDA Approvals

Updated Category News Views 165

NeurAxis Publishes Impressive Financial Results NeurAxis, Inc. (NYSE: NRXS), a pioneering medical technology company focused on developing neuromodulation therapies, has announced remarkable financial results for the third quarter of 2025. The announcement highlights a significant 22% growth in revenues compared to the same period last year, cementing NeurAxis's position...

Continue Reading
Exploring the Future of HealthTech: Market Growth Insights

Updated Category News Views 135

HealthTech Market Overview The healthtech market is experiencing monumental growth fueled by a surge in health consciousness and the increasing demand for preventive care. A significant factor contributing to this expansion is the aging population, coupled with strong governmental initiatives and supportive policies that are shaping market trends. Current Market Valuation...

Continue Reading
FRM's Barrier Restore Cream to Debut at Walmart

Updated Category News Views 15

New Product, New Outlet Roll over, skincare market! There's a fresh player stepping into the retail arena, and it's got some newcomers excited. FRM by Jasmanique is prepped to introduce its “FRM 01: Barrier Restore Cream” at none other than Walmart this fall. Now, you might wonder how this duo is going to shake things up, especially for those of us glued to the ticker...

Continue Reading
Hongli Group Inc. Faces Nasdaq Bid Price Compliance Challenge

Updated Category News Views 142

Hongli Group Inc. Faces Nasdaq Bid Price Compliance Challenge In a recent development, Hongli Group Inc. (Nasdaq: HLP) received a deficiency letter from the Nasdaq Listing Qualifications Department, indicating a non-compliance issue with the minimum bid price required for continued listing. This notice was issued based on the closing bid price of the company's ordinary...

Continue Reading
Kenneth Leech: Facing Fraud Charges for Client Mismanagement

Updated Category News Views 354

Overview of Kenneth Leech's Fraud Charges Kenneth Leech, a veteran in the finance industry and former co-chief investment officer at Western Asset Management Co., now faces alarming legal challenges. Recently charged with running a fraudulent scheme exceeding $600 million, Leech is accused of unethical trading practices where he prioritized certain clients over others....

Continue Reading